medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Number 1

<< Back Next >>

Ann Hepatol 2019; 18 (1)

Celastrol Attenuates Intrahepatic Cholestasis of Pregnancy by Inhibiting Matrix Metalloproteinases-2 and 9

Guo J, Wang Y, Wang N, Bai Y, Shi D

Language: English
References: 42
Page: 40-47
PDF size: 336.14 Kb.


ABSTRACT

Introduction and aim. Matrix metalloproteinase (MMP)-2 and MMP-9 are reported to participate in several pregnancy-related diseases, including intrahepatic cholestasis of pregnancy (ICP), which is a severe liver disorder in pregnant women. Meanwhile, ample evidences have demonstrated that celastrol inhibits the activity and expression of MMPs. The present study aims to examine the effect of celastrol to alleviate symptoms of ICP in rat model. Material and methods. By inducing ICP with 17 - ethinylestradiol in pregnant female rats, we assessed the impact of celastrol administration on symptoms of ICP, such as the rate of bile flow, the level of total bile acids (TBA), and the activities of MMP-2 and -9. Furthermore, the correlations between the levels of MMPs with the examined ICP symptoms were investigated. Results. In rats with ICP, both MMP-2 and -9 exhibited significantly elevated activities, which were inhibited by the administration of celastrol. Furthermore, ICP symptoms such as bile flow rate and total TBA were restored by celastrol. Lastly, there were strong correlations between levels of the two MMPs and TBA. Conclusion. Our findings described for the first time the effects of celastrol to attenuate ICP symptoms through an inhibition of both MMP-2 and -9, providing evidence for a potential role of celastrol as a new drug for the treatment of ICP.


REFERENCES

  1. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009; 15: 2049-66.

  2. Reyes H. Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. J Gastroenterol Hepatol 1997; 12: 211-6.

  3. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40: 467-74. doi: 10.1002/hep.20336.

  4. Nichols AA. Cholestasis of pregnancy: a review of the evidence. J Perinat Neonatal Nurs 2005; 19: 217-25.

  5. Reyes H, Radrigan ME, Gonzalez MC, Latorre R, Ribalta J, Segovia N, Alvarez C, et al. Steatorrhea in patients with intrahepatic cholestasis of pregnancy. Gastroenterology 1987; 93: 584-90.

  6. Mullally BA, Hansen WF. Intrahepatic cholestasis of pregnancy: review of the literature. Obstet Gynecol Surv 2002; 57: 47-52.

  7. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007; 2: 26. doi: 10.1186/1750-1172-2-26.

  8. Riely CA, Bacq Y. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 2004; 8: 167-76. doi: 10.1016/S1089- 3261(03)00131-4.

  9. Lee RH, Goodwin TM, Greenspoon J, Incerpi M. The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol 2006; 26: 527-32. doi: 10.1038/sj.jp.7211545.

  10. Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012-21.

  11. Reyes H. Sex hormones and bile acids in intrahepatic cholestasis of pregnancy. Hepatology 2008; 47: 376-9. doi: 10.1002/hep.22139.

  12. Abedin P, Weaver JB, Egginton E. Intrahepatic cholestasis of pregnancy: prevalence and ethnic distribution. Ethn Health 1999; 4: 35-7. doi: 10.1080/13557859998173.

  13. Beuers U, Pusl T. Intrahepatic cholestasis of pregnancy--a heterogeneous group of pregnancy-related disorders? Hepatology 2006; 43: 647-9. doi: 10.1002/hep.21156.

  14. Heikkinen J, Maentausta O, Tuimala R, Ylostalo P, Janne O. Amniotic fluid bile acids in normal and pathologic pregnancy. Obstet Gynecol 1980; 56: 60-4.

  15. Laatikainen T, Tulenheimo A. Maternal serum bile acid levels and fetal distress in cholestasis of pregnancy. Int J Gynaecol Obstet 1984; 22: 91-4.

  16. Rodrigues CM, Marin JJ, Brites D. Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. Gut 1999; 45: 446-52.

  17. Mays JK. The active management of intrahepatic cholestasis of pregnancy. Curr Opin Obstet Gynecol 2010; 22: 100-3. doi: 10.1097/GCO.0b013e328337238d.

  18. Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. Obstet Gynecol Clin North Am 2010; 37: 269-82. doi: 10.1016/j.ogc.2010.02.011.

  19. Huang WM, Gowda M, Donnelly JG. Bile acid ratio in diagnosis of intrahepatic cholestasis of pregnancy. Am J Perinatol 2009; 26: 291-4. doi: 10.1055/s-0028-1103158.

  20. Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, Becker A, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008;10: 861-8. doi: 10.1016/j.ejheart.2008. 07.005.

  21. Koucky M, Germanova A, Kalousova M, Hill M, Cindrova-Davies T, Parizek A, Svarcova J, et al. Low maternal serum matrix metalloproteinase (MMP)-2 concentrations are associated with preterm labor and fetal inflammatory response. J Perinat Med 2010; 38: 589-96. doi: 10.1515/ JPM.2010.092.

  22. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, Guidi GC. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal 2009; 23: 88-92. doi: 10.1002/ jcla.20295.

  23. Wang Z, Lu S, Liu C, Zhao B, Pei K, Tian L, Ma X. Expressional and epigenetic alterations of placental matrix metalloproteinase 9 in preeclampsia. Gynecol Endocrinol 2010; 26: 96-102. doi: 10.3109/09513590903184100.

  24. Chen Z, Shen Z, Hu L, Lu M, Feng Y. Identification of Matrix Metalloproteinase-2 and 9 as Biomarker of Intrahepatic Cholestasis of Pregnancy. Ann Hepatol 2017; 16: 291-6. doi: 10.5604/16652681.1231589.

  25. Venkatesha SH, Dudics S, Astry B, Moudgil KD. Control of autoimmune inflammation by celastrol, a natural triterpenoid. Pathog Dis 2016; 74. doi: 10.1093/femspd/ftw059.

  26. Kim Y, Kang H, Jang SW, Ko J. Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem 2011; 28: 175-84. doi: 10.1159/000331729.

  27. Li GQ, Zhang Y, Liu D, Qian YY, Zhang H, Guo SY, Sunagawa M, et al. Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-kappaB-mediated matrix metalloproteinase- 9 expression. Int Immunopharmacol 2012; 14: 422-31. doi: 10.1016/j.intimp.2012.08.016.

  28. Li G, Liu D, Zhang Y, Qian Y, Zhang H, Guo S, Sunagawa M, et al. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-kappaB-mediated matrix metalloproteinase-9 expression. PLoS One 2013; 8: e68905. doi: 10.1371/ journal.pone.0068905.

  29. Mi C, Shi H, Ma J, Han LZ, Lee JJ, Jin X. Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncol Rep 2014; 32: 2527-32. doi: 10.3892/or.2014.3535.

  30. Ding QH, Cheng Y, Chen WP, Zhong HM, Wang XH. Celastrol, an inhibitor of heat shock protein 90beta potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes. Eur J Pharmacol 2013; 708: 1- 7. doi: 10.1016/j.ejphar.2013.01.057.

  31. Li Z, Li J, Zhu L, Zhang Y, Zhang J, Yao L, Liang D, et al. Celastrol nanomicelles attenuate cytokine secretion in macrophages and inhibit macrophage-induced corneal neovascularization in rats. Int J Nanomedicine 2016; 11: 6135- 6148. doi: 10.2147/IJN.S117425.

  32. Shi Q, Wang J, Yan S, Zhao J, Li H. Expression of neuropeptide Y and pro-opiomelanocortin in hypothalamic arcuate nucleus in 17alpha-ethinyl estradiol-induced intrahepatic cholestasis pregnant rat offspring. J Obstet Gynaecol Res 2014; 40: 445-52. doi: 10.1111/jog.12206.

  33. Guan Y, Cui ZJ, Sun B, Han LP, Li CJ, Chen LM. Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1alpha-SIRT3 signaling pathway. Int J Mol Med 2016; 37: 1229-38. doi: 10.3892/ ijmm.2016.2549.

  34. Mashige F, Imai K, Osuga T. A simple and sensitive assay of total serum bile acids. Clin Chim Acta 1976; 70: 79-86.

  35. Simon FR, Fortune J, Iwahashi M, Gartung C, Wolkoff A, Sutherland E. Ethinyl estradiol cholestasis involves alterations in expression of liver sinusoidal transporters. Am J Physiol 1996; 271: G1043-52.

  36. Geier A, Dietrich CG, Gerloff T, Haendly J, Kullak-Ublick GA, Stieger B, Meier PJ, et al. Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochim Biophys Acta 2003; 1609: 87-94.

  37. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129: 894-901. doi: 10.1053/j.gastro.2005.06.019.

  38. Merchant SJ, Crocker IP, Baker PN, Tansinda D, Davidge ST, Guilbert LJ. Matrix metalloproteinase release from placental explants of pregnancies complicated by intrauterine growth restriction. J Soc Gynecol Investig 2004; 11: 97-103. doi: 10.1016/j.jsgi.2003.08.005.

  39. Fortunato SJ, Menon R, Lombardi SJ. Amniochorion gelatinase- gelatinase inhibitor imbalance in vitro: a possible infectious pathway to rupture. Obstet Gynecol 2000; 95: 240-4.

  40. Tarantino G, Pezzullo MG, di Minno MN, Milone F, Pezzullo LS, Milone M, Capone D. Drug-induced liver injury due to natural products used for weight loss: a case report. World J Gastroenterol 2009; 15: 2414-7.

  41. Viswanathan L, Patel A. Hepatotoxicity Associated with Herbal Tea Containing Kelp. ACG Case Rep J 2013; 1: 55-7. doi: 10.14309/crj.2013.19.

  42. Al-Olayan EM, El-Khadragy MF, Aref AM, Othman MS, Kassab RB, Abdel Moneim AE. The potential protective effect of Physalis peruviana L. against carbon tetrachloride-induced hepatotoxicity in rats is mediated by suppression of oxidative stress and downregulation of MMP-9 expression. Oxid Med Cell Longev 2014; 2014: 381413. doi: 10.1155/2014/ 381413.




2020     |     www.medigraphic.com